APP inhibitors(Beta amyloid A4 protein inhibitors), TAU inhibitors(Microtubule-associated protein tau inhibitors), α-synuclein inhibitors(Synuclein alpha inhibitors)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseCardiovascular Diseases+ [1]

Active Indication

Alzheimer DiseaseParkinson DiseaseLewy Body Disease+ [2]

Inactive Indication

Mild cognitive disorderYoung onset Parkinson disease

Originator Organization

National Institute on Aging

Active Organization

Annovis Bio, Inc.

Inactive Organization-

License Organization

National Institute on Aging

Annovis Bio, Inc.

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC20H23N3O2

InChIKeyPBHFNBQPZCRWQP-AZUAARDMSA-N

CAS Registry116839-68-0

Clinical Trials associated with Buntanetap

NCT07757204

/ Not yet recruitingPhase 2/3

An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Alzheimer's Disease

This study will examine the long-term safety of buntanetap in participants with AD who have participated in a prior study of buntanetap in AD.

Start Date21 Sep 2026

Sponsor / Collaborator

Annovis Bio, Inc.

NCT07284784

/ RecruitingPhase 2/3

An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Parkinson's Disease

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

Start Date09 Jan 2026

Sponsor / Collaborator

Annovis Bio, Inc.

[+1]

NCT06709014

/ Active, not recruitingPhase 3

A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:
* Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
* Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
* What medical issues do participants have, if any, when taking buntanetap/Posiphen?
Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.
Participants will:
* Take buntanetap/Posiphen or a placebo every day for 18 months
* Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18
* Complete pre- and post-clinic visit phone calls

Start Date04 Feb 2025

Sponsor / Collaborator

Annovis Bio, Inc.

[+2]

100 Clinical Results associated with Buntanetap

100 Translational Medicine associated with Buntanetap

100 Patents (Medical) associated with Buntanetap

Literatures (Medical) associated with Buntanetap

01 May 2026·BIOCHEMISTRY-MOSCOW

A Conjugate of Aminoadamantane and Tetrahydro-γ-Carboline Inhibits Accumulation of Mutant α-Synuclein A53T in the Cellular Model of Proteinopathy

Article

Author: Bachurin, Sergei O ; Kukharsky, Michail S ; Fisenko, Vladimir P ; Kukharskaya, Olga A ; Pukaeva, Nadezhda E ; Pukhov, Sergey A ; Kryshkova, Victoria S ; Stavrovskaya, Alla V ; Nazdracheva, Maya R ; Burak, Marina V ; Rachenkov, Kirill A

Pathological aggregation of α-synuclein is a key event in the development of synucleinopathies, such as Parkinson's disease and Lewy body dementia. Currently, no effective disease-modifying therapy is available, necessitating the search for new therapeutic agents. One promising strategy involves the use of low-molecular-weight compounds capable of inhibiting the formation of toxic protein aggregates. This study evaluates the anti-aggregation properties of EC3222x, a conjugate of pharmacophoric fragments of amantadine and a fluorinated derivative of tetrahydro-γ-carboline. α-Synucleinopathy was modeled in the SH-SY5Y neuroblastoma cell line by transfection with a plasmid vector encoding the mutant human α-synuclein A53T protein. EC3222x at a concentration of 1 µM reduced the number of cells with α-synuclein A53T aggregates. Its efficacy was comparable to that of SynuClean-D and Buntanetap, known inhibitors of α-synuclein aggregation. Treatment with EC3222x reduced both the level of diffusely distributed intracellular α-synuclein and the formation of mature fibrillar aggregates and large aggresomes. Importantly, EC3222x did not affect the accumulation of another aggregation-prone protein, TDP-43, in a similar cellular model, indicating its specificity for α-synuclein. These findings suggest that EC3222x may represent a promising candidate for the development of therapeutic agents targeting synucleinopathies.

01 Dec 2025·Alzheimers & Dementia

Pharmacokinetic characterization of buntanetap in plasma of patients with early Alzheimer’s and Parkinson’s diseases

Article

Author: Maccecchini, Maria L. ; Fang, Cheng ; Morin, Alexander ; Peterson, Matthew J

Abstract:

Background:

Buntanetap (formerly Posiphen) is an orally bioavailable small molecule that improves cognitive function in patients with early Alzheimer’s (AD) and Parkinson’s (PD) diseases. Buntanetap is lipophilic and has high blood‐brain barrier penetrability and brain uptake (10:1 brain:plasma ratio). In SAD and MAD studies, at all doses, buntanetap showed similar profiles, it was absorbed rapidly and cleared from the circulation bi‐phasically, independent of dose. This analysis aims to further evaluate the pharmacokinetics (PK) of buntanetap in AD and PD populations.

Method:

The following parameters were measured across two RCTs for buntanetap doses ranging between 7.5mg‐30mg: C max , T max , AUC 0‐t , AUC 0‐∞ , t 1/2 . In AD (NCT05686044, Phase II/III, N=351), PK samples were obtained at 0h and then 1h, 2h, and 4h after drug administration (0, 7.5mg, 15 mg, 30mg QD). In PD (NCT05357989, Phase III, N=523), two cohorts of PK samples were obtained: sparse and dense (0, 10 mg, 20mg QD). In the sparse group, PK samples were obtained at 0h and then 1.5h after drug administration. In the dense group, PK samples were obtained at 0h and then 1h, 1.5h, and 2h‐10h (hourly) after drug administration.

Result:

Calculated PK parameters for buntanetap in plasma for AD (Table 1) and PD patients (Table 2) had many similarities. C max and AUC 0‐t for AD and PD (dense) increased at the same rate in a dose‐proportional manner; PD (sparse) increased with dose as well, but its response was more muted overall. Mean T max ranged from 1.34‐1.88h across all doses in both AD and PD patients. Mean t 1/2 was comparable and ranged from 1.55‐1.74h in AD and 2.01‐2.57h in PD. The 30mg dose in AD did not follow the increasing trend for AUC 0‐∞ as in the lower doses for AD and PD (dense), which was likely underpowered by the sampling of this measure ( N =2).

Conclusion:

Analyses from two RCTs confirmed similar mean C max , T max , and AUC 0‐t across doses of 7.5mg‐30mg buntanetap in both patients with early AD and PD. These data confirm fast plasma peak, as seen in all of our previous studies, and dose‐dependent exposure to drug, supporting buntanetap’s PK uniformity across AD and PD indications.

01 Dec 2025·Alzheimers & Dementia

A dual 6‐month (stage 1) & 18‐month (stage 2) prospective, randomized, placebo‐controlled, double‐blind, pivotal clinical trial investigating efficacy and safety of buntanetap in early Alzheimer's patients

Article

Author: Morin, Alexander ; Gaines, Melissa ; Fang, Cheng ; Peterson, Matthew J ; Maccecchini, Maria L. ; MacCallum, Sarah J

Abstract:

Background:

Annovis Bio initiated a new pivotal clinical trial in early Alzheimer's disease (AD). This Phase III trial is being conducted to determine whether buntanetap, which inhibits the translation of neurotoxic aggregating proteins, is able to a) duplicate the efficacy seen in our phase IIb study and improve symptomatic effects and b) show potential disease‐modifying effects.

Method:

The study started in March 2025 and is progressing at a good pace. In total, 760 participants will be randomized across up to 100 sites. The study is being conducted at both academic and private sites across the US. Participants are being recruited through sites' databases, physician referrals, and word of mouth. We will collect and summarize data as to site opening, patient inclusion using the plasma pTau217 biomarker, and participant enrollment.

Result:

Tables will be featured on the poster showing the status of the following per July 2025:• An update of the recruiting sites and locations• A US map with all site locations shown as pins, to highlight regional study access• pTau217 selection inclusion/exclusion figures• Current enrollment versus Target enrollment of 760 participants• Actual monthly participant accrual versus projected monthly accrual• Estimated timelines for the 6‐month and 18‐month end of study data readouts• Screen failure rate with breakdown of screen failure reasons

Conclusion:

In summary, we will show the ease of using plasma biomarkers to determine the presence of AD. We will provide updates on total enrollment and the 6‐ and 18‐month data readout timepoints.

152

News (Medical) associated with Buntanetap

22 Oct 2026

·www.biospace.com

Annovis to Attend the CTAD 2026 with Three Presentations

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will attend and present at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, happening November 16-19 in Boston, MA. Presentation details: Title: “Restoring proteostasis in Alzheimer's disease with buntanetap, a small-molecule translational inhibitor of neurotoxic proteins” Presenter: Alexander Morin, PhD, Director, Strategic Communications Type: Oral communications Section: Biotech Showcase 7 Date & time: November 19, 3:52 p.m. ET Title: “Clinical trial design and baseline characteristics of buntanetap’s pivotal study in treating early Alzheimer’s patients” Presenter: Cheng Fang, PhD, Chief Scientific Officer Type: Poster presentation (P025) Section: Clinical Trials – Phase IIB & III Poster display: November 16, 2:00 p.m. – November 17, 5:30 p.m. ET Title: “Predicting blood–brain barrier permeability of late-stage small-molecule drug candidates for Alzheimer's disease using artificial intelligence” Presenter: Alexander Morin, PhD, Director, Strategic Communications Type: Poster presentation (P121) Section: AI-Driven Innovation in Alzheimer’s Therapeutics Poster display: November 16, 2:00 p.m. – November 17, 5:30 p.m. ET “Three presentations at CTAD are a testament to our team’s work advancing buntanetap and pushing the Alzheimer’s field forward,” said Maria Maccecchini, PhD, Founder, President and CEO of Annovis. “Our presentations will cover buntanetap’s innovative mechanism of action, our use of AI for evaluating the Alzheimer’s treatment pipeline, and the updates on our pivotal Phase 3 study in early AD. Together, they reflect our progress as we approach a pivotal data readout in early 2027 and prepare for a New Drug Application. We look forward to sharing all this work and connecting with the Alzheimer’s research community.” About Annovis Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit and follow us on LinkedIn , YouTube , and X . Investor Alerts Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at . Forward-Looking Statements This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law. Contact Information: Annovis Bio Inc. 101 Lindenwood Drive Suite 225 Malvern, PA 19355 Investor Contact: Alexander Morin, Ph.D. Director, Strategic Communications Annovis Bio ir@annovisbio.com

Phase 3Phase 2

23 Sep 2026

·www.biospace.com

Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease

MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge management, in support of the planned New Drug Application (NDA) for buntanetap. Under the collaboration, Annovis will use Weave for drafting, reviewing and managing the NDA documents as the Company heads toward a 6-month top-line data readout from the pivotal Phase 3 AD trial – the data that will form the basis of the submission. Annovis’ regulatory and clinical teams will retain full responsibility for content, verification and final approval of every document submitted to the U.S. Food and Drug Administration (FDA). "Our goal is to have most of the NDA ready before the data readout, so the path from the top-line results to filing is as short as possible," said Eve Damiano, Senior VP, Regulatory Operations at Annovis. "Weave will let our regulatory team spend time on scientific judgment and strategy while providing essential assistance on assembling documents in a faster and more organized way. That is a meaningful advantage as we prepare a submission for an investigational therapy we believe has the potential to help millions of patients still waiting for a treatment that can change their lives." The collaboration follows the completion of enrollment in Annovis’ pivotal Phase 3 AD study ( NCT06709014 ), which enrolled 862 biomarker-confirmed patients, exceeding the original target of 760. The Company aims to reach the database lock for the 6-month treatment period in December 2026, followed by the top-line symptomatic data announcement in March 2027. “Annovis is exactly the kind of company our platform was built for – a team with deep scientific expertise, ambitious timelines, and a vision for the future of AI-driven drug development,” said Brandon Rice, CEO and co-founder of Weave Bio. “NDA submissions are not just about writing documents, they are about weaving years of scientific knowledge into a coherent, traceable narrative. We are privileged to help Annovis do that for a disease area that still has no effective treatment.” Annovis and Weave Bio have aligned their approach around the FDA’s guidance on the use of AI to support regulatory decision-making, issued in January 2025, keeping regulatory professionals in control of AI-assisted drafting, extraction, traceability and review. About Annovis Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit and follow us on LinkedIn , YouTube , and X . Investor Alerts Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at . Forward-Looking Statements This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law. Contact Information: Annovis Bio Inc. 101 Lindenwood Drive Suite 225 Malvern, PA 19355 Investor Contact: Alexander Morin, Ph.D. Director, Strategic Communications Annovis Bio ir@annovisbio.com

25 Aug 2026

·www.biospace.com

Annovis to Host Corporate Update Webinar on September 2, 2026

MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session. The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upcoming milestones. Webinar details Date: Wednesday, September 2, 2026 Time: 4:00 p.m. EDT Presenter: Maria Maccecchini, Ph.D., Founder, President, and CEO Registration link "Annovis is advancing across all its programs, and it is important to share the full scope of that progress with our community," commented Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Several key milestones have been reached: our pivotal Phase 3 AD trial is fully enrolled, and preparations are already underway for the top-line data readout and regulatory submissions, both expected in 2027. We also plan to continue our AD program into an open-label study to generate long-term safety data for buntanetap, with first patients joining in October 2026. On the PD side, the open-label study is well underway, and discussions with Key Opinion Leaders and the FDA are ongoing to initiate the Parkinson's disease dementia program. As we move forward, we are committed to keeping our patient community, stockholders, and everyone following our progress informed at every step." About Annovis Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit and follow us on LinkedIn , YouTube , and X . Investor Alerts Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at . Forward-Looking Statements This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law. Contact Information: Annovis Bio Inc. 101 Lindenwood Drive Suite 225 Malvern, PA 19355 Investor Contact: Alexander Morin, Ph.D. Director, Strategic Communications Annovis Bio ir@annovisbio.com

100 Deals associated with Buntanetap

External Link

KEGG	Wiki	ATC	Drug Bank
D12318	-	-	DB15317

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	United States	Annovis Bio, Inc.	04 Feb 2025
Parkinson Disease	Phase 3	United States	Annovis Bio, Inc.	03 Aug 2022
Parkinson Disease	Phase 3	Germany	Annovis Bio, Inc.	03 Aug 2022
Parkinson Disease	Phase 3	Hungary	Annovis Bio, Inc.	03 Aug 2022
Parkinson Disease	Phase 3	Italy	Annovis Bio, Inc.	03 Aug 2022
Parkinson Disease	Phase 3	Poland	Annovis Bio, Inc.	03 Aug 2022
Parkinson Disease	Phase 3	Spain	Annovis Bio, Inc.	03 Aug 2022
Young onset Parkinson disease	Phase 2	United States	Annovis Bio, Inc.	14 Aug 2020
Lewy Body Disease	Phase 2	-	Annovis Bio, Inc.	-
Mild cognitive disorder	Phase 1	United States	Annovis Bio, Inc.	01 Feb 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05357989 (CTAD2025)	Phase 3	Progressive Supranuclear Palsy Atypical pTau217	187	Buntanetap 20 mg	annjlzepqb(nbmcwjouee) = ulzxtfbrya tzqtcbmafq (mfvwmbzehw ) View more	Positive	01 Dec 2025
NCT05686044 (CTgov)	Phase 2/3	Alzheimer Disease	351	Placebo (Placebo)	jnamxppijc(hwrwbeaxxa) = dipvsqgvps gewkeumyse (lrfwdfrfln, 0.533) View more	-	29 Apr 2025
				Buntanetap/Posiphen (7.5mg Buntanetap/Posiphen)	jnamxppijc(hwrwbeaxxa) = mwzlgqgmcx gewkeumyse (lrfwdfrfln, 0.526) View more
NCT05357989 (CTgov)	Phase 3	Parkinson Disease	523	Placebo (Placebo)	egbvqqesby(fjcxymywpd) = eykpqxdimi vfcqurcljh (yptdsorknh, 0.311) View more	-	03 Mar 2025
				buntanetap/posiphen (10 mg Buntanetap/Posiphen)	egbvqqesby(fjcxymywpd) = mrsiwgfunk vfcqurcljh (yptdsorknh, 0.312) View more
NCT05357989 (Biospace) Manual	Phase 3	Parkinson Disease	-	Buntanetap	lkwtiyblvp(aqdfnyqwuj) = In patients diagnosed with PD for longer than 3 years (MH>3), with measurable declines in MDS-UPDRS Part II, 20mg buntanetap significantly improved MDS-UPDRS Part II, Part III, Part II+III, and Total scores compared to placebo and baseline fummgojodk (squdulfgdw ) View more	Positive	02 Jul 2024
				Placebo
GlobeNewswire Manual	Not Applicable	Alzheimer Disease	-	Buntanetap 15mg	augwpgwjxo(lhbvrldsem) = dkzbyavgtn vmbpuuzlbd (oxuysbnndc )	Positive	11 Jun 2024
				Placebo	augwpgwjxo(lhbvrldsem) = wfgkehxaqz vmbpuuzlbd (oxuysbnndc )
NCT05686044 (Biospace) Manual	Phase 2/3	Alzheimer Disease	325	Buntanetap 7.5 mg	rdbefahjby(saqhdpkfau) = qsqbtiqlcd gddrohpzxk (xqiawthdrs, 0.87)	Positive	29 May 2024
				Buntanetap 15 mg	rdbefahjby(saqhdpkfau) = qkcrmgnlua gddrohpzxk (xqiawthdrs, 0.81)
NCT05686044 (Biospace) Manual	Phase 2/3	Alzheimer Disease	107	Buntanetap	ckukdsrkuf(djimvuvwjs) = bjqoiqvovn zpfgrttpwe (nqbtcbpyup )	Positive	30 Oct 2023
NCT04524351 (CTgov)	Phase 1/2	Young onset Parkinson disease \| Alzheimer Disease	75	Posiphen (Posiphen, 80mg (Parkinson's Participants))	alstmsivxu = jbufwlnrbd wvbowkvcbp (jthvoishnt, nwlslomepm - cfrfpekgzw) View more	-	28 Feb 2023
				Posiphen (Posiphen, 40mg (Parkinson's Participants))	alstmsivxu = tpxvylehih wvbowkvcbp (jthvoishnt, irmnpvwrgj - puvdyhtjun) View more
NCT02925650 (CTAD2022)	Phase 1	Mild cognitive disorder CSF Aβ42/40	19	Posiphen	zrswplgasa(duspmjfapu) = 8/19 participants reported headache either during CSF sampling (4),after the procedure (3), or both (1). 5 had blood patches with rapid resolution of headache. liiiigbwfg (ctdltxacsq )	-	03 Dec 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis